SLC5A2, solute carrier family 5 member 2, 6524

N. diseases: 214; N. variants: 20
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 GeneticVariation disease BEFREE Traditional management of diabetes mellitus has focused on glycemic control, beginning with lifestyle changes, followed by metformin, and then other classes of antiglycemic agents.<sup>1</sup> Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular (CV) events, including CV death, myocardial infarction (MI) and heart failure, and slow progression of renal dysfunction, including prevention of end-stage kidney disease (ESKD).<sup>2-3</sup> Because initial clinical trials included mostly patients with baseline HbA1c >7%, current guidelines have recommended this class as add-on therapy for patients whose HbA1c is not at goal, typically ≥7%.<sup>1</sup> We hypothesized that there would be similar benefits on CV and renal endpoints regardless of baseline HbA1c, including those with HbA1c <7%. 31707795 2020
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment. 31132013 2019
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE Several ongoing dedicated renal outcomes trials will provide further guidance on the potential clinical role of SGLT2 inhibitors in slowing the development and progression of renal impairment in individuals with T2DM. 30929540 2019
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE Ongoing SGLT-2 inhibitor CVOTs will help clarify the potential of these drugs to treat T2D comorbid with different forms of HF (HF with preserved vs reduced ejection fraction) and different degrees of renal dysfunction, and in individuals with T2D vs pre-diabetes or normal glucose metabolism. 30767677 2019
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE Renal impairment is currently a contraindication to SGLT2 inhibitor use largely due to limited anti-hyperglycaemic efficacy. 31377891 2019
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE The current review article summarises these aspects and discusses possible mechanisms with SGLT2 inhibitors in protecting heart failure and renal dysfunction in diabetic patients. 31456521 2019
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE Of these, only the DPP-4 inhibitor linagliptin can be used across all stages of renal impairment without dosing restrictions or concerns regarding dose escalation, and all SGLT2 inhibitors are contraindicated when eGFR <45 mL/min/1.73m<sup>2</sup>. 29667921 2018
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 AlteredExpression disease BEFREE SGLT2 inhibition relative to placebo was associated with preservation in serum creatinine levels or initial increases followed by return to baseline levels in patients with renal impairment, but levels were preserved in patients without renal impairment. 29482993 2018
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE Caution is advised when prescribing SGLT-2 inhibitors to patients with moderately impaired renal function and those at risk for volume depletion and hypotension. 27977314 2017
CUI: C1565489
Disease: Renal Insufficiency
Renal Insufficiency
0.100 Biomarker disease BEFREE The beneficial effects of SGLT2 inhibitors on various aspects of renal function make them an attractive choice in patients with (and possibly without) diabetes-associated renal impairment. 27748201 2017